DE60213230D1 - Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit - Google Patents

Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit

Info

Publication number
DE60213230D1
DE60213230D1 DE60213230T DE60213230T DE60213230D1 DE 60213230 D1 DE60213230 D1 DE 60213230D1 DE 60213230 T DE60213230 T DE 60213230T DE 60213230 T DE60213230 T DE 60213230T DE 60213230 D1 DE60213230 D1 DE 60213230D1
Authority
DE
Germany
Prior art keywords
inhibitors
kappa
dry eye
treat dry
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60213230T
Other languages
English (en)
Other versions
DE60213230T2 (de
Inventor
A Gamache
M Yanni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Publication of DE60213230D1 publication Critical patent/DE60213230D1/de
Application granted granted Critical
Publication of DE60213230T2 publication Critical patent/DE60213230T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60213230T 2001-05-21 2002-05-17 Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit Expired - Lifetime DE60213230T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29249501P 2001-05-21 2001-05-21
US292495P 2001-05-21
PCT/US2002/015859 WO2002095704A1 (en) 2001-05-21 2002-05-17 Use of nf-kappa-b inhibitors to treat dry eye disorders

Publications (2)

Publication Number Publication Date
DE60213230D1 true DE60213230D1 (de) 2006-08-31
DE60213230T2 DE60213230T2 (de) 2006-11-23

Family

ID=23124921

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213230T Expired - Lifetime DE60213230T2 (de) 2001-05-21 2002-05-17 Verwendung von NF-Kappa.B Inhibitoren zur Behandlung von Augentrockenheit

Country Status (17)

Country Link
US (1) US6696453B2 (de)
EP (1) EP1393277B1 (de)
JP (1) JP2004527578A (de)
CN (1) CN1509462A (de)
AT (1) ATE333273T1 (de)
AU (1) AU2002309963B2 (de)
BR (1) BR0209965A (de)
CA (1) CA2447883A1 (de)
CY (1) CY1105220T1 (de)
DE (1) DE60213230T2 (de)
DK (1) DK1393277T3 (de)
ES (1) ES2263785T3 (de)
MX (1) MXPA03010632A (de)
PL (1) PL367286A1 (de)
PT (1) PT1393277E (de)
WO (1) WO2002095704A1 (de)
ZA (1) ZA200308769B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05003063A (es) * 2002-09-20 2005-05-27 Alcon Inc Uso de inhibidores de la sintesis de citosina para el tratamiento de trastornos de ojos secos.

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991759A (en) 1975-10-28 1976-11-16 Alza Corporation Method and therapeutic system for treating aqueous deficient dry eye
US4131651A (en) 1977-10-25 1978-12-26 Barnes-Hind Pharmaceuticals, Inc. Treatment of dry eye
US4409205A (en) 1979-03-05 1983-10-11 Cooper Laboratories, Inc. Ophthalmic solution
US4370325A (en) 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
US4883658A (en) 1986-04-28 1989-11-28 Holly Frank J Ophthalmic solution for treatment of dry-eye syndrome
US4744980A (en) 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
US4804539A (en) 1986-07-28 1989-02-14 Liposome Technology, Inc. Ophthalmic liposomes
US4818537A (en) 1986-10-21 1989-04-04 Liposome Technology, Inc. Liposome composition for treating dry eye
US4966773A (en) 1986-11-25 1990-10-30 Alcon Laboratories, Inc. Topical ophthalmic compositions containing microfine retinoid particles
US4914088A (en) 1987-04-02 1990-04-03 Thomas Glonek Dry eye treatment solution and method
US5278151A (en) 1987-04-02 1994-01-11 Ocular Research Of Boston, Inc. Dry eye treatment solution
US4996209A (en) 1988-06-20 1991-02-26 Alcon Laboratories, Inc. Ophthalmic antiinflammatory compositions comprising S(+)-flurbiprofen
US5075104A (en) 1989-03-31 1991-12-24 Alcon Laboratories, Inc. Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
US5174988A (en) 1989-07-27 1992-12-29 Scientific Development & Research, Inc. Phospholipid delivery system
US5583150A (en) 1989-08-18 1996-12-10 Alcon Laboratories, Inc. 5-methyl-isoxazole-4-carboxylic acid anilides and 2-hydroxyethylidene-cyano acetic anilides for the treatment of ocular diseases
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
ZA912797B (en) 1990-05-29 1992-12-30 Boston Ocular Res Dry eye treatment process and solution
ATE132366T1 (de) 1990-05-29 1996-01-15 Boston Ocular Res Zusammensetzung zur behandlung von dry eye erkrankungen
DE4028906A1 (de) 1990-09-12 1992-03-19 Paz Arzneimittelentwicklung Arzneimittel sowie deren herstellung und deren verwendung bei der bekaempfung von schmerzen und/oder entzuendungen und/oder fieber an tieren und menschen
DE69212850T2 (de) 1991-01-15 1997-03-06 Alcon Lab Inc Verwendung von Karrageenan in topischen ophthalmologischen Zusammensetzungen
ZA927277B (en) 1991-10-02 1993-05-19 Boston Ocular Res Dry eye treatment process and solution.
DE4140184C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Flurbiprofen enthaltendes Arzneimittel
DE69326836T2 (de) 1992-04-21 2000-02-24 Schepens Eye Res Inst Androgentherapie am auge beim sjögrensyndrom
US5958912A (en) * 1992-04-21 1999-09-28 The Schepens Eye Research Institute, Inc. Ocular therapy in keratoconjunctivitis sicca using topically applied androgens of TGF-β
US5290572A (en) 1992-08-06 1994-03-01 Deo Corporation Opthalmic composition for treating dry eye
US5686436A (en) 1993-05-13 1997-11-11 Hiv Diagnostics, Inc. Multi-faceted method to repress reproduction of latent viruses in humans and animals
US5561161A (en) 1994-03-25 1996-10-01 Oxigene, Inc. Methods of administering and pharmaceutical formulations containing n-substituted benzamides and/or acid addition salts thereof
FR2718441B1 (fr) 1994-04-07 1996-06-28 Bioxytech Nouveaux composés de structure benzisoséléna-zoline et -zine, leur procédé de préparation et leurs applications thérapeutiques.
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
AU715430B2 (en) 1995-08-14 2000-02-03 Optigenex, Inc. Carotenoid-nicotinamide-zinc compositions and methods of treatment using same
US5696166A (en) 1995-10-31 1997-12-09 Yanni; John M. Compositions containing hydroxyeicosatetraenoic acid derivatives and methods of use in treating dry eye disorders
WO1997020578A1 (en) * 1995-12-04 1997-06-12 University Of Miami Non-preserved topical corticosteroid for treatment of dry eye, filamentary keratitis, and delayed tear clearance
US6028111A (en) 1996-03-08 2000-02-22 Oxigene, Inc. Compositions and use of benzamides and nicotinamides as anti-inflammatory agents
US6100299A (en) 1996-03-08 2000-08-08 Oxigene, Inc. N-acetyl 3-chloroprocainamide, acid addition salts thereof, and methods of use
US6046185A (en) 1996-07-11 2000-04-04 Inflazyme Pharmaceuticals Ltd. 6,7-oxygenated steroids and uses related thereto
US6071904A (en) 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
US5916910A (en) 1997-06-04 1999-06-29 Medinox, Inc. Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore
US6207458B1 (en) 1998-05-07 2001-03-27 University Of Washigton/Stowers Insitute For Medical Research Proteins capable of regulating NF-κB JNK and apoptosis pathways and methods of using the same
JP2002520355A (ja) * 1998-07-14 2002-07-09 アルコン ラボラトリーズ， インコーポレイテッド 非アレルギー性眼炎症障害を処置および眼新生血管形成を予防する医薬製造のための、１１−（３−ジメチルアミノプロピリデン）−６，１１−ジヒドロジベンズ［ｂ，ｅ］オキセピン−２−酢酸の使用
WO2000043000A1 (fr) 1999-01-20 2000-07-27 Kyowa Hakko Kogyo Co., Ltd. Inhibiteurs de proteasome
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
DE60011889T2 (de) 1999-04-27 2005-07-14 Novartis Ag 2,4-diamino-3-hydroxycarboxylsäurederivate als proteasome inhibitoren

Also Published As

Publication number Publication date
BR0209965A (pt) 2004-04-06
WO2002095704A8 (en) 2003-09-18
US6696453B2 (en) 2004-02-24
AU2002309963B2 (en) 2007-03-01
PL367286A1 (en) 2005-02-21
US20030008854A1 (en) 2003-01-09
EP1393277A1 (de) 2004-03-03
EP1393277B1 (de) 2006-07-19
CN1509462A (zh) 2004-06-30
PT1393277E (pt) 2006-09-29
JP2004527578A (ja) 2004-09-09
ES2263785T3 (es) 2006-12-16
DE60213230T2 (de) 2006-11-23
WO2002095704A9 (en) 2003-02-27
ZA200308769B (en) 2005-01-26
ATE333273T1 (de) 2006-08-15
MXPA03010632A (es) 2004-03-09
CY1105220T1 (el) 2010-03-03
WO2002095704A1 (en) 2002-11-28
DK1393277T3 (da) 2006-10-30
CA2447883A1 (en) 2002-11-28

Similar Documents

Publication Publication Date Title
CY1107531T1 (el) Χρηση αναστολεων πρωτεασομης για την αγωγη των διαταραχων ξηρου οφθαλμου
DE60142590D1 (de) Verwendung von Botulinum Toxin zur Behandlung von post-operative Schmerzen
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE419856T1 (de) Verwendung von rimexolon zur behandlung von augentrockenheit
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
ATE279921T1 (de) Verwendung von antikonvulsiven derivaten zur behandlung der cluster headache
ATE345811T1 (de) Methoden zur verwendung von neurotrophin 3 (nt-3) zur behandlung von gastrointestinalen hypomobilitätsstörungen
DE50114605D1 (de) No-thien-2-yl-essigsaure-derivate und ihre verwendung zur behandlung von migraine bzw. schmerz
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE287713T1 (de) Verwendung von riluzol zur behandlung multipler sklerose
ATE333273T1 (de) Verwendung von nf-kappa.b inhibitoren zur behandlung von augentrockenheit
ATE281165T1 (de) Verwendung von pramipexol zur behandlung von restless-legs-syndrom
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE264101T1 (de) Verwendung von thioamidoxazolidinonen zur behandlung von knochenresorption und osteoporose
ATE360425T1 (de) Verwendung von quetiapin für die behandlung von kokain-abhängigkeit
ATE278401T1 (de) Verwendung von riluzol zur behandlung von akustischen traumazuständen
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
DE59904564D1 (de) Verwendung von acetylcholinesterase-inhibitoren zur behandlung von delirien
ATE275949T1 (de) Verwendung von diminazen-di-aceturat und/oder pentamidin zur behandlung von malaria
DE69926996D1 (de) Verwendung von riluzol zur behandlung der retinalischemie
DE60007864D1 (de) Verwendung von antileukoprotease zur behandlung von endometriose
ATE432359T1 (de) Modulation der s6-kinaseaktivität zur behandlung von adipositas
ATE292970T1 (de) Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden
DE50207854D1 (de) Verwendung von rutinen und aescinen zur behandlung aurikulärer durchblutungsstörungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition